Excess Risk of Monoclonal Gammopathy in Patients With Gaucher Disease
- 18 February 2026
- journal article
- Published by Wiley in American Journal of Hematology
- Vol. 101 (6) , 1182-1186
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (P30 CA 240139)
- Tow Foundation
This publication has 15 references indexed in Scilit:
- Three decades of cancer data in patients with Gaucher disease: Insights from the world's largest referral centerMolecular Genetics and Metabolism, 2025
- Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significanceEuropean Journal of Haematology, 2023
- Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher RegistryAmerican Journal of Hematology, 2022
- A bone paradigm challenging the standard model of myeloma oncogenesisCritical Reviews in Oncology/Hematology, 2022
- Hematological manifestations and complications of Gaucher diseaseExpert Review of Hematology, 2021
- Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United StatesAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2020
- Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathyMolecular Genetics and Metabolism, 2020
- Saposin C is a frequent target of paraproteins in Gaucher disease‐associated MGUS/multiple myelomaBritish Journal of Haematology, 2018
- Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health and Nutrition Examination SurveyBlood Cancer Journal, 2017
- Gaucher Disease and Cancer: Concept and ControversyInternational Journal of Cell Biology, 2011